公开(公告)号：US11891373B2

公开(公告)日：2024-02-06

申请号：US17494938

申请日：2021-10-06

Applicant: PFIZER INC.

Inventor： Eric Christian Hansen ,  Christopher Scott Seadeek ,  Anil Mahadeo Rane

IPC: C07D401/04 ,  A61K31/4439

CPC classification number: C07D401/04 ,  A61K31/4439 ,  C07B2200/13

Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.

公开(公告)号：US20220017548A1

公开(公告)日：2022-01-20

申请号：US17365213

申请日：2021-07-01

Applicant: Pfizer Inc.

Inventor： Robert Steven Kania ,  Padmavani Bezawada ,  Emma Louise Hawking ,  Rohit Jaini ,  Samir Kulkarni ,  Matthew Nathan O'Brien Laramy ,  Jonathan Richard Lillis ,  Suman Luthra ,  Dafydd Rhys Owen ,  Klimentina Dimitrova Pencheva ,  Martin Youngjin Pettersson ,  Anil Mahadeo Rane ,  Matthew Forrest Sammons ,  Bradley Paul Sullivan ,  Andrew John Thiel ,  Martyn David Ticehurst ,  Jamison Bryce Tuttle ,  Robert Louis Hoffman

IPC: C07F9/572 ,  A61P31/14

Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US10815240B2

公开(公告)日：2020-10-27

申请号：US16502703

申请日：2019-07-03

Applicant: Pfizer Inc.

Inventor： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC: C07D487/04 ,  C07D249/08

Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US11926642B2

公开(公告)日：2024-03-12

申请号：US17365213

申请日：2021-07-01

Applicant: Pfizer Inc.

Inventor： Robert Steven Kania ,  Padmavani Bezawada ,  Emma Louise Hawking ,  Rohit Jaini ,  Samir Kulkarni ,  Matthew Nathan O'Brien Laramy ,  Jonathan Richard Lillis ,  Suman Luthra ,  Dafydd Rhys Owen ,  Klimentina Dimitrova Pencheva ,  Anil Mahadeo Rane ,  Matthew Forrest Sammons ,  Bradley Paul Sullivan ,  Andrew John Thiel ,  Martyn David Ticehurst ,  Jamison Bryce Tuttle ,  Robert Louis Hoffman

IPC: C07F9/572 ,  A61P31/14

CPC classification number: C07F9/5728 ,  A61P31/14 ,  C07B2200/13

Abstract: The invention relates to compounds of formula I




wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US11254684B2

公开(公告)日：2022-02-22

申请号：US17036849

申请日：2020-09-29

Applicant: Pfizer Inc.

Inventor： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC: C07D487/04 ,  C07D249/08

Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US12018031B2

公开(公告)日：2024-06-25

申请号：US17572089

申请日：2022-01-10

Applicant: Pfizer Inc.

Inventor： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC: C07D487/04 ,  C07D249/08

CPC classification number: C07D487/04 ,  C07D249/08 ,  C07B2200/13

Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20220127274A1

公开(公告)日：2022-04-28

申请号：US17572089

申请日：2022-01-10

Applicant: Pfizer Inc.

Inventor： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC: C07D487/04 ,  C07D249/08

Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20220024894A1

公开(公告)日：2022-01-27

申请号：US17494938

申请日：2021-10-06

Applicant: PFIZER INC.

Inventor： Eric Christian Hansen ,  Christopher Scott Seadeek ,  Anil Mahadeo Rane

IPC: C07D401/04 ,  A61K31/4439

Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.

公开(公告)号：US20210009601A1

公开(公告)日：2021-01-14

申请号：US17036849

申请日：2020-09-29

Applicant: Pfizer Inc.

Inventor： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC: C07D487/04 ,  C07D249/08

Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20200123159A1

公开(公告)日：2020-04-23

申请号：US16502703

申请日：2019-07-03

Applicant: Pfizer Inc.

Inventor： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC: C07D487/04 ,  C07D249/08

Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.